Alzheimer's Drug

Federal officials are struggling with a decision that could determine the future of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm, and whether significant numbers of patients use it. In January, Medicare plans to issue a preliminary decision on covering the expensive...

In a surprise move, Biogen Inc (NASDAQ: BIIB) announced that it would slash the price of its controversial Alzheimer's drug Aduhelm in half from $56,000 to $28,000. In Q3, Biogen generated a mere 300k from Aduhelm sales, indicating that less than 100 Alzheimer's...

Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determine the pharmacokinetics, safety, and tolerability of AL001 and target doses for...

AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease (AD). The trial expansion...

LMTX, a drug designed to battle the effects of Alzheimer's disease, recently failed a large phase III trial, but did show signs of success when the drug was given to people who are already taking other Alzheimer medications. The drug is produced by a company called TauRX Pharmaceuticals. According...